PT - JOURNAL ARTICLE AU - Zhao, Naisi AU - Ruan, Mengyuan AU - Koestler, Devin C. AU - Lu, Jiayun AU - Marsit, Carmen J. AU - Kelsey, Karl T. AU - Platz, Elizabeth A. AU - Michaud, Dominique S. TI - Epigenome-wide scan identifies differentially methylated regions for lung cancer using pre-diagnostic peripheral blood AID - 10.1101/2021.02.04.21251138 DP - 2021 Jan 01 TA - medRxiv PG - 2021.02.04.21251138 4099 - http://medrxiv.org/content/early/2021/02/06/2021.02.04.21251138.short 4100 - http://medrxiv.org/content/early/2021/02/06/2021.02.04.21251138.full AB - Background To reduce lung cancer burden in the US, a better understanding of biological mechanisms in early disease development could provide new opportunities for risk stratification.Methods In a nested case-control study, we measured blood leukocyte DNA methylation levels in pre-diagnostic samples collected from 430 men and women in the 1989 CLUE II cohort. Median time from blood drawn to diagnosis was 14 years for all participants. We compared DNA methylation levels by case/control status to identify novel genomic regions, both single CpG sites and differentially methylated regions (DMRs), while controlling for known DNA methylation changes associated with smoking using a previously described pack-years based smoking methylation score. Stratification analyses were conducted by time from blood draw to diagnosis, histology, and smoking status.Results We identified sixteen single CpG sites and forty DMRs significantly associated with lung cancer risk (q < 0.05). The identified genomic regions were associated with genes including H19, HOXA4, RUNX3, BRICD5, PLXNB2, and RP13. For the single CpG sites, the strongest association was noted for cg09736286 in the DIABLO gene (OR [for 1 SD] = 2.99, 95% CI: 1.95-4.59, P-value = 4.81 × 10−7). For the DMRs, we found that CpG sites in the HOXA4 region were hypermethylated in cases compared to controls.Conclusion The single CpG sites and DMRs that we identified represented significant measurable differences in lung cancer risk, providing new insights into the biological processes of early lung cancer development and potential biomarkers for lung cancer risk stratification.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by 2018 American Association for Cancer Research (AACR)-Johnson & Johnson Lung Cancer Innovation Science (18-90-52-MICH).Note: The funders had no role in the design of the study; the collection, analysis, and interpretation of the data; the writing of the manuscript; and the decision to submit the manuscript for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Institutional Review Board at Johns Hopkins University Bloomberg School of Public Health and at Tufts University.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets generated during the current study are available from the corresponding author on reasonable request and will be deposited into dbGaP within 1 year.